National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States

被引：63

作者：

Ostrom, Quinn T. ^{[1
,2
,3
,4
,10
]}

Shoaf, Madison L. ^{[2
]}

Cioffi, Gino ^{[1
,5
]}

Waite, Kristin ^{[1
,5
]}

Kruchko, Carol ^{[1
]}

Wen, Patrick Y. ^{[6
]}

Brat, Daniel J. ^{[7
]}

Barnholtz-Sloan, Jill S. ^{[5
,8
]}

Iorgulescu, J. Bryan ^{[9
,11
]}

机构：

[1] Cent Brain Tumor Registry US, Hinsdale, IL USA

[2] Duke Univ, Dept Neurosurg, Sch Med, Durham, NC USA

[3] Duke Univ, Preston Robert Tisch Brain Tumor Ctr, Sch Med, Durham, NC USA

[4] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA

[5] NCI, Trans Divis Res Program, Div Canc Epidemiol & Genet, Bethesda, MD USA

[6] Dana Farber Canc Inst, Dept Med Oncol, Div Neurooncol, Boston, MA USA

[7] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL USA

[8] NCI, Ctr Biomed Informat & Informat Technol, Bethesda, MD USA

[9] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX USA

[10] Duke Univ, Dept Neurosurg, Sch Med, 571 Res Dr,MSRB-1,Rm 442, Durham, NC 27710 USA

[11] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA

来源：

NEURO-ONCOLOGY | 2023年 / 25卷 / 04期

关键词：

diffuse glioma; glioblastoma; IDH mutation; MGMT promoter methylation; survival; PHASE-III; ADJUVANT TEMOZOLOMIDE; HIGH-GRADE; RADIOTHERAPY; MGMT; CLASSIFICATION; GLIOBLASTOMA; CHEMOTHERAPY; CONCOMITANT; RESECTION;

D O I：

10.1093/neuonc/noac198

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Molecularly-defined diffuse glioma types-including IDH-wildtype glioblastoma, IDH-mutant astrocytoma, IDH-mutant 1p/19q-codeleted oligodendroglioma, and H3 K27M-mutant diffuse midline glioma-were incorporated into U.S. cancer registry reporting for individuals with brain tumors beginning in 2018. We leveraged these new data to estimate the national-level overall survival (OS) patterns associated with glioma integrated diagnoses. Methods Individuals diagnosed with diffuse gliomas in 2018 and had brain molecular marker data were identified within the U.S. National Cancer Database. OS was estimated using Kaplan-Meier methods and stratified by WHO CNS grade, age, sex, tumor size, treatment, extent of resection, and MGMT promoter methylation. Additionally, the effects of WHO CNS grade were examined among individuals with IDH-wildtype astrocytic gliomas. Results 8651 individuals were identified. One-year OS was 53.7% for WHO grade 4 IDH-wildtype glioblastomas; 98.0%, 92.4%, and 76.3% for WHO grade 2, 3, and 4 IDH-mutant astrocytomas, respectively; 97.9% and 94.4% for WHO grade 2 and 3 IDH-mutant 1p/19q-codeleted oligodendrogliomas, respectively; and 55.9% for H3 K27M-mutant diffuse midline gliomas. Among IDH-wildtype glioblastomas, median OS was 17.1 months and 12.4 months for methylated and unmethylated MGMT promoters. Additionally, IDH-wildtype diffuse astrocytic gliomas reported as WHO grade 2 or 3 demonstrated longer OS compared to grade 4 tumors (both P < .001). Conclusions Our findings provide the initial national OS estimates for molecularly-defined diffuse gliomas in the United States and illustrate the importance of incorporating such data into cancer registry reporting.

引用

页码：799 / 807

页数：9

共 32 条

[11] The Misclassification of Diffuse Gliomas: Rates and Outcomes [J].

Iorgulescu, J. Bryan ;

Torre, Matthew ;

Harary, Maya ;

Smith, Timothy R. ;

Aizer, Ayal A. ;

Reardon, David A. ;

Barnholtz-Sloan, Jill S. ;

Perry, Arie .

CLINICAL CANCER RESEARCH, 2019, 25 (08) :2656-2663

[12] CODEL: phase III study of RT, RT plus TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design [J].

Jaeckle, Kurt A. ;

Ballman, Karla, V ;

van den Bent, Martin ;

Giannini, Caterina ;

Galanis, Evanthia ;

Brown, Paul D. ;

Jenkins, Robert B. ;

Cairncross, J. Gregory ;

Wick, Wolfgang ;

Weller, Michael ;

Aldape, Kenneth D. ;

Dixon, Jesse G. ;

Anderson, S. Keith ;

Cerhan, Jane H. ;

Wefel, Jeffrey S. ;

Klein, Martin ;

Grossman, Stuart A. ;

Schiff, David ;

Raizer, Jeffrey J. ;

Dhermain, Frederick ;

Nordstrom, Donald G. ;

Flynn, Patrick J. ;

Vogelbaum, Michael A. .

NEURO-ONCOLOGY, 2021, 23 (03) :457-467

[13] A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma [J].

Jenkins, Robert B. ;

Blair, Hilary ;

Ballman, Karla V. ;

Giannini, Caterina ;

Arusell, Robert M. ;

Law, Mark ;

Flynn, Heather ;

Passe, Sandra ;

Felten, Sara ;

Brown, Paul D. ;

Shaw, Edward G. ;

Buckner, Jan C. .

CANCER RESEARCH, 2006, 66 (20) :9852-9861

[14] Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis [J].

Kavouridis, Vasileios K. ;

Boaro, Alessandro ;

Dorr, Jeffrey ;

Cho, Elise Y. ;

Iorgulescu, J. Bryan ;

Reardon, David A. ;

Arnaout, Omar ;

Smith, Timothy R. .

JOURNAL OF NEUROSURGERY, 2020, 133 (05) :1291-1301

[15] Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors [J].

Kruchko, Carol ;

Gittleman, Haley ;

Ruhl, Jennifer ;

Hofferkamp, Jim ;

Ward, Elizabeth M. ;

Ostrom, Quinn T. ;

Sherman, Recinda L. ;

Jones, Sandra F. ;

Barnholtz-Sloan, Jill S. ;

Wilson, Reda J. .

NEURO-ONCOLOGY PRACTICE, 2019, 6 (05) :330-339

[16] Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma [J].

Lamba, Nayan ;

Chukwueke, Ugonma N. ;

Smith, Timothy R. ;

Ligon, Keith L. ;

Aizer, Ayal ;

Reardon, David A. ;

Iorgulescu, J. Bryan .

JAMA ONCOLOGY, 2020, 6 (12) :1972-1974

[17] The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary [J].

Louis, David N. ;

Perry, Arie ;

Reifenberger, Guido ;

von Deimling, Andreas ;

Figarella-Branger, Dominique ;

Cavenee, Webster K. ;

Ohgaki, Hiroko ;

Wiestler, Otmar D. ;

Kleihues, Paul ;

Ellison, David W. .

ACTA NEUROPATHOLOGICA, 2016, 131 (06) :803-820

[18] Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma [J].

Mackay, Alan ;

Burford, Anna ;

Carvalho, Diana ;

Izquierdo, Elisa ;

Fazal-Salom, Janat ;

Taylor, Kathryn R. ;

Bjerke, Lynn ;

Clarke, Matthew ;

Vinci, Mara ;

Nandhabalan, Meera ;

Temelso, Sara ;

Popov, Sergey ;

Molinari, Valeria ;

Raman, Pichai ;

Waanders, Angela J. ;

Han, Harry J. ;

Gupta, Saumya ;

Marshall, Lynley ;

Zacharoulis, Stergios ;

Vaidya, Sucheta ;

Mandeville, Henry C. ;

Bridges, Leslie R. ;

Martin, Andrew J. ;

Al-Sarraj, Safa ;

Chandler, Christopher ;

Ng, Ho-Keung ;

Li, Xingang ;

Mu, Kun ;

Trabelsi, Saoussen ;

H'mida-Ben Brahim, Dorra ;

Kisljakov, Alexei N. ;

Konovalov, Dmitry M. ;

Moore, Andrew S. ;

Montero Carcaboso, Angel ;

Sunol, Mariona ;

de Torres, Carmen ;

Cruz, Ofelia ;

Mora, Jaume ;

Shats, Ludmila I. ;

Stavale, Joao N. ;

Bidinotto, Lucas T. ;

Reis, Rui M. ;

Entz-Werle, Natacha ;

Farrell, Michael ;

Cryan, Jane ;

Crimmins, Darach ;

Caird, John ;

Pears, Jane ;

Monje, Michelle ;

Debily, Marie-Anne .

CANCER CELL, 2017, 32 (04) :520-+

[19] Incident Cases Captured in the National Cancer Database Compared with Those in US Population Based Central Cancer Registries in 2012-2014 [J].

Mallin, Katherine ;

Browner, Amanda ;

Palis, Bryan ;

Gay, Greer ;

McCabe, Ryan ;

Nogueira, Leticia ;

Yabroff, Robin ;

Shulman, Lawrence ;

Facktor, Matthew ;

Winchester, David P. ;

Nelson, Heidi .

ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (06) :1604-1612

[20] Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis [J].

Olson, Robert A. ;

Brastianos, Priscilla K. ;

Palma, David A. .

JOURNAL OF NEURO-ONCOLOGY, 2011, 105 (02) :325-335

← 1 2 3 4 →